ClinicalTrials.gg
RecruitingNCT06224530LEVHIPPROUpdated Aug 5, 2026

Investigating the Effect of a Single-dose of Levetiracetam on Brain Function, Chemistry and Cognitive Performance in Psychosis Risk

An interventional study of Levetiracetam and Placebo in Psychosis, sponsored by King's College London. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by King's College London · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Psychotic Disorders by King's College London — 12 open to participants now, 12 under way, none of them phase 3. Psychotic Disorders · King's College London.

Planned enrollment
3rd of 18
69 · median 24
Started
2024
with 2 others
No phase
15 of 26
5 open now
Primary completion
2026-08
later than 3 of 11 live
Registered
17th of 26
by date

Among the 26 studies in Psychotic Disorders by King's College London, this one is the 3rd largest by planned enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2024, is one of 15 with no phase, reaches primary completion later than 3 of the 11 other live ones, and was the 17th registered.

Psychotic Disorders

1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

12 of the 26 studies in Psychotic Disorders by King's College London are open now, in 3 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Psychotic Disorders by King's College London, or all of them as a file.
02

Study summary

Background

Psychosis is a mental health condition that affects around 3 in 100 people in their lifetime. Most treatments for psychosis target a brain chemical called dopamine but they don't work for everyone and don't address many of the symptoms.

People with psychosis and people at risk of developing psychosis show differences in a part of the brain called the hippocampus, such as smaller size and increased activity. This hyperactivity may be associated with cognitive difficulties (thinking and memory).

The basis of this hippocampal hyperactivity is thought to be a deficit in excitation and inhibition of brain cells. Excitation causes brain cells to send signals more frequently, and inhibition causes cells to send signals less frequently. A balance between these signals is important for the brain, including the hippocampus, to function properly.

Approach

Levetiracetam is a medication that is widely used to treat epilepsy and which helps balance excitation-inhibition in the brain. We will use brain imaging, using Magnetic Resonance Imaging (MRI), to test if levetiracetam can help reduce hippocampal hyperactivity, alter connectivity and change levels of brain chemicals in people who are at risk of developing psychosis.

Participants (18-40 years), identified as at risk of psychosis through the Outreach and Support in South London (OASIS) teams, will attend an initial visit at the Institute of Psychiatry, Psychology \& Neuroscience. This will involve questions about experiences and feelings, assessment of thinking and memory, and a blood test. They will then attend two scanning visits at the Centre for Neuroimaging Sciences, during which they will take capsules of either levetiracetam or placebo (in a randomised order) before having a 60 mins MRI scan. The MRI scan will look at blood flow to the hippocampus, resting activity, activity during a cognitive task and levels of brain chemicals.

A case-control sample of 33 healthy individuals aged 18-40 will be recruited from Greater London. We will recruit a healthy control (HC) sample to establish the presence of hippocampal dysfunction in our CHR-P group by comparing the MRI data for CHR-P under the placebo condition with that of the HC sample. The HC individuals will attend the screening visit and one scanning visit. They will not receive any medication.

Funded by the Wellcome Trust and conducted by King's College London researchers, the study spans 2-3 months per participant.

Impact

Our study will provide important evidence about how levetiracetam affects brain function, and how this relates to cognition. This knowledge may lead to innovative approaches for understanding and treating psychosis early.

Read the detailed description

Can the acute administration of levetiracetam modulate hippocampal rCBF, resting-state fMRI connectivity, cognitive performance and cortical glutamatergic levels in CHR individuals?

Study Design:

Investigators will address the above research question using a randomised, double-blind, placebo-paired, within-subject crossover design on 36 participants at CHR for psychosis. The study will enrich the CHR sample and reduce heterogeneity by selecting patients who present with positive symptoms (score 3-5 on Clinical Assessment of At Risk Mental State (CAARMS) unusual thought content or non-bizarre ideas subscales), as known proxy measures of hippocampal dysfunction (Allen et al., 2018a; Modinos et al., 2018; Tregellas et al., 2014).

Previous rCBF studies including our own (Allen et al., 2016, 2018a; Percie du Sert et al., 2023) have robustly demonstrated hippocampal hyperactivity in CHR individuals compared to healthy controls. Nevertheless, the presence of hippocampal dysfunction in our CHR group will be established by comparing the MRI data for CHR under placebo condition with that of 33 healthy controls recruited from the Greater London area.

Sample:

36 individuals at CHR of psychosis 33 healthy control participants

Methodology:

CHR-P participants will undergo:

  • Screening visit
  • Scanning Visit 1 (under placebo/levetiracetam)
  • Scanning Visit 2 (under levetiracetam/placebo)

HC participants will undergo:

  • Screening visit (without blood test)
  • Scanning Visit 1 (without administration of any medication)

SCREENING VISIT:

The screening visit will last approximately 2 hours (CHR-P) or 1.5 hours (HCs) and will be conducted at the IoPPN by a qualified study researcher. Procedures during this visit, except blood sampling for CHR-P and cognitive assessments, may also be conducted remotely over the telephone or video call (e.g. Microsoft Teams) in the case that a face-to-face meeting is not possible or feasible without putting participant and researcher at risk. All participants that undergo screening are logged into a screening log associated with the study by the study researcher, to which only authorized members of the research team can access (Dr Modinos and trained research workers).

- Procedures involved in the screening visit:

  • Consent / capacity assessment
  • Sociodemographic information, including medical, family, substance use history (including current pregnancy and breast feeding)
  • Brief assessment of inclusion/exclusion criteria - including MRI safety questionnaire
  • Blood sampling (CHR-P only)_
  • Clinical assessment (see below)
  • Cognitive assessment (see below)

Clinical assessment:

  • Psychopathology will be assessed using the CAARMS.
  • Anxiety and mood will be assessed using the Hamilton Anxiety and Depression Rating Scale (HAM-A/D).
  • Social functioning, disability, adjustment, and interactions, and emotional empathy will be assessed using the Social and Occupational Functioning Scale (SOFAS, Global Functioning Social and Role, GF-S/R)

Cognitive assessment:

  • Wechsler Adult Intelligence Scale (WAIS-III) short version (Current IQ)
  • National Adult Reading Test (NART) (Premorbid IQ)
  • Pattern separation task
  • Cambridge Neuropsychological Test Automated Battery (CANTAB)- specific battery used for previous multi-site study PSYSCAN

Study drug / placebo (CHR only):

The study drug (500mg levetiracetam) and placebo (75mg ascorbic acid) capsules will be encapsulated, stored and dispensed by the South London and Maudsley (SLaM) NHS Foundation Trust Pharmacy. Levetiracetam / placebo capsules will be dispensed in visually identical capsules for blinding purposes.

SCANNING VISITS CHR-P

MRI scans will take place at the Centre for Neuroimaging Sciences, IoPPN. Scanning visit 1 and 2 will be identical, the only difference being the administration of either placebo or levetiracetam.

Schedule:

  • 90 min Arrive at the centre
  • 80 min ID, neuroimaging consent and pre-scan checklist. Basic physical examination (weight, height, blood pressure, and standard systems exam). Urine drug screen (UDS) and urine pregnancy test (for female participants).
  • 60min Dose of levetiracetam or placebo administered.
  • 25 min Administration of emotion recognition and spatial span tasks. T = 0 MRI scan

    • 60min End scan. Subject escorted to recovery room. Subject provided with snack and refreshment.
    • 70 min Post-scan monitoring.

Scanning Visits HCs MRI scans will take place at the Centre for Neuroimaging Sciences, IoPPN..

  • 45 mins Arrive at the centre

    -- 40 mins ID, neuroimaging consent and recap of pre-scan checklist. Measurement of weight and height. UDS.

  • 30 mins Administration of emotion recognition and spatial span tasks. T = 0 MRI scan

    • 60min End scan. Subject provided with optional snack and refreshment.

Emotion Recognition Task The CANTAB Emotion Recognition Task66 will be administered after the levetiracetam/placebo dose (CHR-P only) and before MRI imaging. This computer-generated paradigm measures the six basic facial emotional expressions: anger, disgust, fear, happiness, sadness and surprise. Participants are presented with computer-morphed faces expressing one emotion, with each face shown for 200 ms. Participants are then required to select the displayed emotion from the six basic emotions or choose a neutral option. The task lasts approximately 12 minutes. Outcome measures include percentage and number of correct or incorrect responses and overall response latencies, which can be analysed either across individual emotions or across all emotions.

Spatial Span Task The CANTAB Spatial Span66 assesses visuospatial working memory capacity and will be administered after the levetiracetam/placebo dose (CHR-P) and before MRI imaging. In this computerised task, participants are shown white squares on a screen, some of which briefly change colour in a variable sequence. Participants are required to select the boxes that changed colour in the same order displayed by the computer, either as shown or in reverse. The sequence ranges from two to nine boxes changing colour, with varied colour throughout. Outcome measures include span length errors, number of attempts, and latency.

MRI imaging:

Neuroimaging data will be acquired using an MRI scanner at the Centre for Neuroimaging Sciences, IoPPN. Each scanning session will involve 1 hour waiting time prior to scanning to allow for the drug to exert its effects, followed by 60 minutes of scanning:

  • Scene processing task.
  • Glutamate and GABA Magnetic Resonance Spectroscopy (MRS)
  • Resting-State fMRI
  • Arterial Spin Labelling (ASL)
  • Structural MRI

Drug / Placebo Administration (CHR only):

An oral dose of levetiracetam (500 mg) or placebo (75mg ascorbic acid) will be given 1 h before the beginning of the neuroimaging acquisition. This time interval is chosen because levetiracetam has peak plasma concentration (Cmax) 1 - 1.5 hours after administration. It is rapidly and almost completely absorbed following oral administration with >95% bioavailability.

Half of the sample will be given placebo in the first experimental session and levetiracetam in the second experimental session, and the other half will be given levetiracetam in the first experimental session.

Timing of Assessments:

Scanning visit 1 must be completed within three months of the screening visit. The timing of scanning visit 2 is relative to scanning visit 1. This will result in a comparable study completion period between participants. Scanning visit 2 occurs 3 weeks +/- 1 week after scanning visit 1, to allow for complete washout. Levetiracetam has a half life of 6-8 hours in healthy adults.

Duration of study:

The study will take 24 - 36 months. Each participant will be enrolled in the study for approximately 3 months from recruitment to completion of the study (screening visit + scanning visit 1 + scanning visit 2), although note that participants will only be required to attend for a few hours for each visit.

Sample size and power calculation:

Investigators will aim to recruit 36 CHR participants to allow for potential drop out rate of 20%, aiming for at least 29 subjects with both scans complete.

There are no existing studies of rCBF or other fMRI changes with levetiracetam in CHR individuals. Studies with levetiracetam administration in participants Mild Cognitive Impairment (MCI) (n= 17) have shown that levetiracetam significantly reduced mean task-based hippocampal BOLD-fMRI activation (t = 2.537, p = 0.022) to a level that no longer significantly differed from controls (n=22)(Bakker et al., 2012).

A recent study completed by the Modinos group (unpublished data) has shown that acute diazepam administration in 24 CHR individuals significantly reduced rCBF in the right (t=-4.30, FDR-corrected p\<0.001) and left hippocampus (t=-2.69, FDR-corrected p=0.015).

Multiple studies have demonstrated significantly higher hippocampal rCBF for CHR individuals compared to healthy controls (Allen et al., 2016, 2018b). Allen et al (2018) showed an effect size of 0.62 for increased rCBF in the hippocampal region of interest (ROI) in CHR compared to controls (Allen et al., 2016, 2018a). Based on this, a sample size of 29 subjects will have at least 0.90 power (alpha= 0.05, two-tailed paired t-test) to detect a significant change in rCBF.

Based on the effect size of 0.62 from Allen et al (2018), with 33 CHR participants and 33 HC we will have at least 0.80 power (alpha= 0.05, independent samples t-test) to detect a significant difference in rCBF.

These estimates are conservative as this study benefits from a within-subject crossover design, which will reduce variability and confounding, and enrichment of the sample to reduce inter-subject variability.

Image Analysis and Statistics

Hypothesis 1. CHR-P MRI scans in the placebo condition will significantly differ from MRI scans obtained from HCs.

Differences in MRI outcomes will be analysed via one-way ANOVAs, controlling for confounding variables (age, sex) as covariates of no interest in the design.

Hypothesis 2. Levetiracetam (vs placebo) will decrease hippocampal rCBF in people at CHR-P of psychosis.

rCBF data will be pre-processed using the Automatic Software for ASL Processing (ASAP) 2.0 toolbox52.

Differences in hippocampal rCBF between levetiracetam and placebo conditions will be tested using a hippocampal ROI approach, via a paired t-test (p\<0.05 family-wise error corrected).

Hypothesis 3. Levetiracetam (vs placebo) will improve hippocampal resting-state functional connectivity.

Resting-state fMRI data will be analysed using a seed-based approach for the hippocampus in the CONN-fMRI Functional Connectivity toolbox53. Differences between levetiracetam and placebo will be tested using paired t-tests. Dynamic connectivity will be analysed using edge-centric analysis in Matlab54. The frequency and amplitude of co-fluctuation peaks for levetiracetam vs placebo will be compared using paired t-tests (p\<0.05 family-wise error corrected).

The Amplitude of Low-Frequency Fluctuation (ALFF) analysis will be performed using the current recommended methodology. The ALFF data for levetiracetam vs placebo will be compared using paired t-tests (p\<0.05 family-wise error corrected).

Hypothesis 4. Levetiracetam (vs placebo) will improve hippocampal fMRI activation during a scene processing task.

The scene processing fMRI task first level analysis will include separate regressors for scene, face and scramble conditions. For second-level analysis we will use a contrast estimating the difference in average response to scene and face, versus the scrambled condition. We will perform whole-brain analysis, and ROI analysis for the hippocampus, for levetiracetam vs placebo conditions using paired t-tests (p\<0.05 family-wise error corrected). Performance on the 1-back task will be measured using mean hit rate, correct rejection rate, and reaction time for each condition. To examine differences in performance we will conduct within-subject ANOVAs on hit rate, correct rejection rate, and reaction time, with group as a within-subject factors.

Hypothesis 5. Levetiracetam (vs placebo) will decrease levels of cortical glutamatergic metabolites and increase levels of GABA.

1H-MRS data will be analysed according to current recommendations. Changes in Glx levels (glutamate + glutamine) and GABA between levetiracetam and placebo conditions will be assessed using a paired t-test (p\<0.05, two-tailed).

Hypothesis 6. Levetiracetam (vs placebo) will improve accuracy and latency in an emotion recognition task.

Drug effects on emotion recognition task accuracy and reaction time will be analysed using repeated-measures ANOVA, with drug (levetiracetam, placebo) and emotion (anger, disgust, fear, happiness, sadness, and surprise) as within-subject factors. Post-hoc paired t-tests with Bonferroni corrections will be used for pairwise comparisons between the drug and placebo conditions. Significance will be set at p\<0.05.

Hypothesis 7. Levetiracetam (vs placebo) will improve visuospatial working memory capacity in a spatial span working memory.

Drug effects on span length, errors, number of attempts, and latency will be analysed using repeated-measures ANOVA with drug condition as a within-subject factor. Post-hoc paired t-tests with Bonferroni corrections will be used for pairwise comparisons between the drug and placebo conditions. Significance will be set at p\<0.05.

Hypothesis 8. The above neuroimaging measures are associated with changes in emotion recognition and visuospatial working memory capacity.

Multiple regression analyses will be used to examine the correlations between the changes in the neuroimaging measures (levetiracetam vs placebo) and changes in visuospatial working memory and emotion recognition performance. Significance will be set at p\<0.05.

Hypothesis 9. The above neuroimaging measures are associated with baseline cognitive function, clinical symptoms and blood markers.

Pearson's correlation (Bonferroni corrected p\<0.05, two-tailed) will be used to test for associations between changes in the MRI measures for levetiracetam and placebo and baseline symptom severity (CAARMS symptom scores and CANTAB cognitive performance), to determine whether those CHR-P individuals with higher symptom severity / cognitive dysfunction show a greater change in MRI measures after levetiracetam.

Pearson's correlation (Bonferroni corrected p\<0.05, two-tailed) will be used to test for associations between peripheral blood markers and hippocampal rCBF, and cognitive performance.

03

Conditions studied

  • Psychosis

Browse trials for

Keywords

  • Clinical high risk
  • Levetiracetam
  • Psychosis risk
  • Neuroimaging
  • Hippocampus
  • GABA
  • Glutamate
  • SV2A
  • Experimental medicine
  • Magnetic Resonance Spectroscopy
  • Magnetic Resonance Imaging
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

CHR-P inclusion criteria

  1. Age range 18-40 years
  2. Capacity to consent to participation in the study
  3. Inclusion into attenuated psychosis group as assessed by the CAARMS
  4. Scores 3-5 on CAARMS unusual thought content or non-bizarre ideas subscales

CHR-P exclusion criteria:

  1. Past episode of psychosis
  2. Current exposure to drugs with strong GABAergic or glutamatergic effects (benzodiazepines, anticonvulsants, mood stabilisers, zopiclone, zolpidem, ketamine, opiates, atomoxetine, memantine)
  3. Current/recent exposure to any antipsychotic medication
  4. Diagnosis of any neurological disorder, including epilepsy
  5. Current pregnancy/breastfeeding
  6. Severe renal impairment
  7. Known allergy to levetiracetam
  8. to MRI scanning
  9. IQ\<70 as determined with WAIS-III
  10. CHR-P individuals are not deemed to have a full-blown mental health disorder. However, in the event that a CHR-P individual is acutely ill and lacking capacity to consent, they will not be approached to take part in this study.

HC inclusion criteria

  1. Age range 18-40 years
  2. Capacity to consent to participation in the study

HC exclusion criteria:

  1. Personal history of mental health conditions
  2. Any first-degree relative with a psychotic disorder
  3. Diagnosis of any neurological disorder, including epilepsy
  4. Currently pregnant, breastfeeding, or trying to conceive
  5. Current exposure to drugs with strong GABAergic or glutamatergic effects (benzodiazepines, anticonvulsants, mood stabilisers, zopiclone, zolpidem, ketamine, opiates, atomoxetine, memantine)
  6. Current/recent exposure to any antipsychotic medication
  7. Contraindication to MRI scanning
  8. IQ\<70 as determined with WAIS-III
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
69 participants (estimated)

Study arms

  • Experimental
    Levetiracetam, then Placebo

    Participants will receive two levetiracetam 250mg capsules on the first scanning visit. On the second scanning visit they will receive two 37.5mg capsules of ascorbic acid.

    Drug: Levetiracetam · Drug: Placebo

  • Experimental
    Placebo, then Levetiracetam

    Participants will receive two 37.5mg capsules of ascorbic acid on the first scanning visit. On the second scanning visit they will receive two levetiracetam 250mg capsules.

    Drug: Levetiracetam · Drug: Placebo

Interventions

  • Single dose of 500mg levetiracetam The capsules of levetiracetam and placebo will be visibly the same.

    Also known as: Keppra

  • DrugPlacebo

    Single dose of 75mg ascorbic acid. The capsules of levetiracetam and placebo will be visibly the same.

06

What researchers measure

Primary outcomes

  1. Magnetic resonance Imaging (MRI) measure of rCBF using arterial spin labelling (ASL) in the hippocampus.

    3D pseudo-Continuous Arterial Spin Labelling (3D-pCASL) sequence will be used to measure rCBF.

    Time frame: 1 hour after single dose levetiracetam vs placebo

Secondary outcomes

  1. Brain functional resting-state fMRI measures (including Amplitude of Low-Frequency Fluctuation (ALFF))

    A state-of-the-art resting-state fMRI sequence will be used to measure intrinsic activity and connectivity of the hippocampus.

    Time frame: 1 hour after single dose levetiracetam vs placebo

  2. Brain functional MRI activation during a scene processing task.

    Scene processing tasks have been used before in fMRI studies with the general population and patients with early psychosis. Research has demonstrated that perceptual scene processing involves the hippocampus, and this is not just dependent on memory encoding. This task demonstrated reduced fMRI activation and increase cerebral blood volume in the anterior hippocampus of patients with early psychosis compared to controls. This task will last approximately 5 minutes.

    Time frame: 1 hour after single dose levetiracetam vs placebo

  3. Levels of GABAergic and glutamatergic metabolites in the anterior cingulate cortex (ACC) as measured by proton magnetic resonance spectroscopy (1H-MRS).

    1H-MRS spectra will be acquired in the ACC using a well-established local protocol for glutamate and GABA quantification (MEGA-PRESS)

    Time frame: 1 hour after single dose levetiracetam vs placebo

  4. Emotion recognition performance

    The CANTAB Emotion Recognition Task will be administered after the levetiracetam/placebo dose (CHR-P only) and before MRI imaging.

    Time frame: 30 mins after single dose of levetiracetam vs placebo and at screening visit

  5. Spatial Span working memory performance

    Visuospatial working memory performance as measured by the CANTAB Spatial Span working memory task measured 30mins after administration of levetiracetam/placebo, before the MRI scan.

    Time frame: 30 mins after administration of levetiracetam/placebo and at screening visit for CHR participants

07

Study locations

1 of 1 sites recruiting
  • Institute of Psychiatry, Psychology and Neuroscience, King's College London
    London, London SE5 8AF, United Kingdom
    Recruiting
    • Abigail Gee, MBChB, MSc, MRCPsych · Contactabigail.gee@kcl.ac.uk · +44 (0)20 7848 0927
    • Gemma Modinos, PhD FYAE MAE · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Aug 2026, 25 months after the start.

Of 460 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 25 months is below that.

Counting every sponsor, half of 462 studies reached it within 34 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2024
First posted
Jan 25, 2024
StartActual
Jul 19, 2024
Primary completionEst.
Aug 30, 2026
CompletionEst.
Aug 30, 2026
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06224530
Responsible party
Sponsor
First posted
Jan 25, 2024
Start date
Jul 19, 2024
Primary completion
Aug 30, 2026 (estimated)
Completion
Aug 30, 2026 (estimated)
Last update
Aug 5, 2026

Study contacts

Abigail A Gee, MBChB MSc
Contact
abigail.gee@kcl.ac.uk
Gemma Modinos, BSc MSc PhD
principal investigator · King's College London

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion